{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:15:17Z","timestamp":1787008517312,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1179","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize contemporary UK practice in prostate MRI reporting and pathways, and identify priorities for standardization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between February and April 2025, a questionnaire was distributed by the British Society of Urogenital Radiology to UK-based consultant radiologists who report prostate MRI. It contained 34 questions, covering 6 domains: demographics; MRI protocols; biopsy; reporting preferences; imaging pathways; and attitudes towards accreditation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-seven radiologists representing 52 NHS Trusts across all nations of the UK responded. Key findings include variable patient preparation for MRI including anti-spasmodic medication (69.2% administering) and instruction related to bowel preparation (13.5%). Trusts (100) were performing MRI prior to biopsy for suspected cancer; 73.1% using multiparametric MRI. When reporting prostate MRI for suspected cancer, 28.6% document only a PI-RADS score, 27.3% only a Likert score, with 44.1% stating both. The PI-QUAL score is moderately well known (71.4% of respondents) but not in routine use (7.8%). Transperineal prostate biopsy was performed at 88.5% of Trusts, with biopsy more likely to be performed by urologists (98.1% of Trusts) or urology nurses (36.5%) than radiologists (26.9%). Patients with high- or very high-risk prostate cancer undergo variable staging pathways, with university teaching hospitals more likely to offer PSMA PET\/CT than other settings (33.3% vs 12.0%, P\u2009=\u2009.023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This survey shows the current state of UK prostate MRI practice, including universal pre-biopsy MRI. It identifies areas for standardization, including MRI protocols, scoring systems, and national staging guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>Provides an up-to-date snapshot on prostate MRI within the UK.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjr\/tqaf312","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T04:09:05Z","timestamp":1765771745000},"page":"442-449","source":"Crossref","is-referenced-by-count":3,"title":["Prostate MRI in the United Kingdom: a survey of current practice by the British Society of Urogenital Radiology"],"prefix":"10.1093","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-844X","authenticated-orcid":false,"given":"Samuel J","family":"Withey","sequence":"first","affiliation":[{"name":"Department of Radiology, The Royal Marsden NHS Foundation Trust , London SW3 6JJ,","place":["United Kingdom"]},{"name":"British Society of Urogenital Radiology , Devon,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iztok","family":"Caglic","sequence":"additional","affiliation":[{"name":"British Society of Urogenital Radiology , Devon,","place":["United Kingdom"]},{"name":"Centre for Medical Imaging, University College London , London WC1E 6AG,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-1474","authenticated-orcid":false,"given":"Tristan","family":"Barrett","sequence":"additional","affiliation":[{"name":"British Society of Urogenital Radiology , Devon,","place":["United Kingdom"]},{"name":"Department of Radiology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust , Cambridge CB2 0QQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"2026032003512763400_tqaf312-B1","doi-asserted-by":"crossref","first-page":"e2434622","DOI":"10.1001\/jamanetworkopen.2024.34622","article-title":"Incidence, prevalence, and survival of prostate cancer in the UK","volume":"7","author":"Tan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026032003512763400_tqaf312-B2"},{"key":"2026032003512763400_tqaf312-B3","author":"EAU Guidelines"},{"key":"2026032003512763400_tqaf312-B4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"2026032003512763400_tqaf312-B5","doi-asserted-by":"crossref","first-page":"e000643","DOI":"10.1136\/bmjonc-2024-000643","article-title":"Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation","volume":"4","author":"Dodkins","year":"2025","journal-title":"BMJ Oncol"},{"key":"2026032003512763400_tqaf312-B6","doi-asserted-by":"crossref","first-page":"894.e11","DOI":"10.1016\/j.crad.2019.09.129","article-title":"Prostate mpMRI in the UK: the state of the nation","volume":"74","author":"Davies","year":"2019","journal-title":"Clin Radiol"},{"key":"2026032003512763400_tqaf312-B7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2025.13722","article-title":"Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial","volume":"334","author":"Ng","year":"2025","journal-title":"JAMA"},{"key":"2026032003512763400_tqaf312-B8","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","article-title":"PI-QUAL version 2: an update of a standardized scoring system for the assessment of image quality of prostate MRI","volume":"34","author":"de Rooij","year":"2024","journal-title":"Eur Radiol"},{"key":"2026032003512763400_tqaf312-B9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2026032003512763400_tqaf312-B10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euo.2023.04.007","article-title":"Prostate imaging after focal ablation (PI-FAB): a proposal for a scoring system for multiparametric MRI of the prostate after focal therapy","volume":"6","author":"Giganti","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2026032003512763400_tqaf312-B11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bju.15285","article-title":"Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting","volume":"127","author":"Barrett","year":"2021","journal-title":"BJU Int"},{"key":"2026032003512763400_tqaf312-B12","author":"Royal College of Radiologists","year":"2025"},{"key":"2026032003512763400_tqaf312-B13","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","article-title":"ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training","volume":"30","author":"de Rooij","year":"2020","journal-title":"Eur Radiol"},{"key":"2026032003512763400_tqaf312-B14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"},{"key":"2026032003512763400_tqaf312-B15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-018-1019-5","article-title":"The Cambridge prognostic groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study","volume":"16","author":"Gnanapragasam","year":"2018","journal-title":"BMC Med"},{"key":"2026032003512763400_tqaf312-B16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00330-017-4940-7","article-title":"Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate","volume":"28","author":"Ullrich","year":"2018","journal-title":"Eur Radiol"},{"key":"2026032003512763400_tqaf312-B17","doi-asserted-by":"crossref","first-page":"216.e9","DOI":"10.1016\/j.crad.2017.07.013","article-title":"Effect of hyoscine butylbromide on prostate multiparametric MRI anatomical and functional image quality","volume":"73","author":"Slough","year":"2018","journal-title":"Clin Radiol"},{"key":"2026032003512763400_tqaf312-B18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.09.035","article-title":"Evaluating biparametric versus multiparametric magnetic resonance imaging for diagnosing clinically significant prostate cancer: an international, paired, noninferiority, confirmatory observer study","volume":"87","author":"Twilt","year":"2025","journal-title":"Eur Urol"},{"key":"2026032003512763400_tqaf312-B19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2020.03.002","article-title":"Additional value of dynamic contrast-enhanced sequences in multiparametric prostate magnetic resonance imaging: data from the PROMIS study","volume":"78","author":"Bosaily","year":"2020","journal-title":"Eur Urol"},{"key":"2026032003512763400_tqaf312-B20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41391-024-00896-y","article-title":"Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022","volume":"28","author":"Soerensen","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026032003512763400_tqaf312-B21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(25)00100-7","article-title":"Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial","volume":"26","author":"Bryant","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026032003512763400_tqaf312-B22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2026032003512763400_tqaf312-B23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"2026032003512763400_tqaf312-B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12089-9","article-title":"ESUR: opportunities for PSMA-PET\/CT and whole-body MRI in advanced prostate cancer","author":"Woo","year":"2025","journal-title":"Eur Radiol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqaf312\/65879645\/tqaf312.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1179\/442\/65879645\/tqaf312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1179\/442\/65879645\/tqaf312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:51:37Z","timestamp":1773993097000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1179\/442\/8379826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":24,"journal-issue":{"issue":"1179","published-online":{"date-parts":[[2025,12,14]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqaf312","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,14]]}}}